Evolv Technologies (NASDAQ: EVLV) posts Q2 results and officer change

Rhea-AI Filing Summary

Evolv Technologies Holdings, Inc. filed a current report describing two developments. The company announced that it released its financial results for the fiscal quarter ended June 30, 2025, with the full details provided in a separate press release furnished as an exhibit.

The company also reported that Michael Ellenbogen, its Chief Innovation Officer and a member of the Board of Directors, informed the company on August 13, 2025 that he will resign from his Chief Innovation Officer role effective September 5, 2025, citing new time commitments. His decision is stated to be not due to any disagreements with the company. He will continue to serve as a member of the Board and will receive compensation as a non-employee director under the company’s director compensation policy.

0001805385False00018053852025-08-142025-08-140001805385us-gaap:CommonClassAMember2025-08-142025-08-140001805385evlv:WarrantsToPurchaseOneShareOfClassCommonStockMember2025-08-142025-08-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 14, 2025

Evolv Technologies Holdings, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-39417

84-4473840

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

500 Totten Pond Road, 4th Floor Waltham, Massachusetts						02451
(Address of principal executive offices)						(Zip Code)

(781) 374-8100

Registrant’s telephone number, including area code

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A common stock, par value $0.0001 per share

EVLV

The Nasdaq Stock Market

Warrants to purchase one share of Class A common stock

EVLVW

The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02    Results of Operations and Financial Condition.

On August 14, 2025, Evolv Technologies Holdings, Inc. (the “Company”) announced financial results for the fiscal quarter ended June 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On August 13, 2025, Mr. Michael Ellenbogen, Chief Innovation Officer and a member of the Board of Directors (the “Board”) of the Company, informed the Company that he would be resigning as Chief Innovation Officer, effective as of September 5, 2025, citing new time commitments. Mr. Ellenbogen’s decision to resign is not due any disagreements with the Company. Mr. Ellenbogen will continue to serve as a member of the Board and will be eligible to receive compensation as a non-employee director pursuant to the Company's Director Compensation Policy.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press Release, dated August 14, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Evolv Technologies Holdings, Inc.
Date: August 14, 2025			By:			/s/ John Kedzierski
			Name:			John Kedzierski
			Title:			Chief Executive Officer

FAQ

What did Evolv Technologies Holdings, Inc. (EVLV) report in this 8-K?

The company reported that it announced financial results for the fiscal quarter ended June 30, 2025 and disclosed the planned resignation of its Chief Innovation Officer from that officer role while he remains on the Board of Directors.

What period do the latest Evolv Technologies (EVLV) financial results cover?

The financial results announced by Evolv Technologies Holdings, Inc. cover the fiscal quarter ended June 30, 2025, with full details contained in a press release furnished as Exhibit 99.1.

Which executive is resigning at Evolv Technologies Holdings, Inc. (EVLV) and when is it effective?

Michael Ellenbogen, the company’s Chief Innovation Officer and a member of the Board of Directors, informed the company that he will resign as Chief Innovation Officer effective September 5, 2025.

Why is Evolv’s Chief Innovation Officer resigning from his role?

The filing states that Mr. Michael Ellenbogen is resigning as Chief Innovation Officer citing new time commitments, and that his decision is not due to any disagreements with the company.

Will Michael Ellenbogen remain involved with Evolv Technologies (EVLV) after resigning as Chief Innovation Officer?

Yes. Mr. Ellenbogen will continue to serve as a member of the Board of Directors and will be eligible to receive compensation as a non-employee director under the company’s Director Compensation Policy.

Where can investors find the detailed quarterly results for Evolv Technologies (EVLV)?

The detailed financial results for the fiscal quarter ended June 30, 2025 are provided in a press release that is furnished as Exhibit 99.1 to this report.